Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Q3 2023 Earnings Presentation
20 slides from Clearpoint Neuro's earnings presentation, Nov 9, 2023
Slide 1: ClearPoint Neuro: When your path is unclear, we point the way
CLEARPOINT NEURO WHEN YOUR PATH IS t WE POINT THE WAY. Nasdaq: CLPT November 2023
Slide 2: Forward-looking statements
© 2 0 2 3 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size
Slide 3: Neuro navigation and device company; biologics and drug delivery enabler
© 2 0 2 3 C L E A R P O I N T N E U R O 3 A Neuro Navigation and Device Company with: • A growing portfolio of Navigation, Therapy and Access Devices supporting DBS, Laser Ablation, Biopsy and Brain Computer Interface implantation • An expanding global installed base of more than 65 centers A Biolog
Slide 4: Company at a glance
4 100+ $23-$25m (A) $24.3m (B) Solana Beach, CA Key Products: Marked Platforms Capital Equipment Razor / Razorblade model with ~95% of revenue from single- use disposables and services 60% (B,D) ~5% ~95% Disposables and Services © 2 0 2 3 C L E A R P O I N T N E U R O Carlsbad, CA London, UK (A) Est
Slide 5: Primary challenge
© 2 0 2 3 C L E A R P O I N T N E U R O 5 PRIMARY CHALLENGE For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head MRI is the best imaging tool for the brain Large, metallic frames are not MRI compatible Video source: https://www.youtube.com/watch?v=PsL9B7
Slide 6: Applications: neuromodulation, drug delivery, biopsy, laser therapy
© 2 0 2 3 C L E A R P O I N T N E U R O 6 Neuromodulation Parkinson’s Disease, OCD, Epilepsy, Dystonia Drug Delivery Approved Rare Genetic Disorders + 30 Indications in Clinical Trials Biopsy Glioblastoma, Diffuse Intrinsic Pontine Glioma, etc. Laser Therapy Epilepsy, Tumors, Parkinson’s, Essential
Slide 7: SmartFrame XG, Array Tower and robotic system
© 2 0 2 3 C L E A R P O I N T N E U R O 7 SmartFrame XG Trajectory Tower with ClearPoint 2.1 Software SmartFrame Array Tower with “virtual array” Software and next generation robotic system with increased automation and enabling software* ClearPoint plans to translate more than 10 years of experienc
Slide 8: ClearPoint Maestro Brain Model
© 2 0 2 3 C L E A R P O I N T N E U R O 8 1. Shape Constrained, triangular mesh model enables point- based correspondence across multiple subjects. 2. Fast and capable of peri-procedural imaging without CPU acceleration. 3. Import DICOM volume bitmasks into ClearPoint software today to assist Neuros
Slide 9: Broad and growing user base
Broad and Growing! User Base of. rig Neurdiurgery Ce = Centers: in the US, EU, Brazil n Francisco” ¥ # mf Charles River Labs. ‘Stanford University University of Michigan’ __ Charles River Lal * Lucile Packard this Hospital University of Minnesota ~. Children’s Mercy Hos} ir * Carilion Clinic 4 _ CHO
Slide 10: Visualase
© 2 0 2 3 C L E A R P O I N T N E U R O 10 VISUALASE *In approved clinical trials and preclinical studies.
Slide 11: Revenue by category, 2014-2023
11© 2 0 2 3 C L E A R P O I N T N E U R O $ M ill io n s $7.4 $11.2 $12.8 $7.4 $5.7$4.6 $3.6 $16.3 $23 $25 $20.6 $2.6 $3.4 $4.0 $5.2 $5.4 $7.1 $6.3 $8.1 $9.1 $0.9 $1.1 $1.0 $1.4 $0.8 $1.7 $1.5 $1.4 $2.3 $0.6 $1.2 $0.8 $0.6 $1.1 $2.4 $5.0 $6.8 $9.1 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Bi
Slide 12: Target indications and potential addressable market
Parkinson’s Disease 1,000,0001 60,0001 • $270 M - $1.35 B Drug Resistant Epilepsy 1,000,0002 11,0003 • $49.5 M - $198 M Refractory Essential Tremor 3,500,0004 60,0005 $180 M - $1.08 B Brain Tumors (n=3)6 35,0007,8 13,3007,8 $33.3 M - $300 M Severe Obsessive-Compulsive Disorder 500,0009,10 10,0009,10
Slide 13: Citations and footnotes
© 2 0 2 3 C L E A R P O I N T N E U R O 13 1. “Parkinson’s Disease Statistics,” Parkinson’s News Today, https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older 2. Neurona Therapeutics. (2021 November 4). Neurona Therapeutic
Slide 14: Active development programs
© 2 0 2 3 C L E A R P O I N T N E U R O 14 First Use in 2022 Active Development Programs* Fu n ct io n al N av ig at io n & T h e ra p y B io lo gi cs & D ru g D e liv e ry , A cc e ss T e ch n o lo gi e s ClearPoint Neuro Navigation Software v. 2.1 ClearPoint Maestro® Brain Model ClearPoint Orchest
Slide 15: Training and demonstration center
© 2 0 2 3 C L E A R P O I N T N E U R O 15 • Simulated training experience for surgeons and staff to perform mock procedures and provide development pipeline feedback • Showcase new technologies to Pharmaceutical and BCI partners • Home for Clinical Specialists to support cases remotely without trav
Slide 16: New manufacturing facility
© 2 0 2 3 C L E A R P O I N T N E U R O 16 • 2,500 Sq. Ft. Clean Room • Designed for best-in-class lean manufacturing, warehouse and shipping expertise • Will be available for Neurosurgeon and Pharmaceutical site visits in late 2023
Slide 17: 4 pillar growth strategy by 2025
NEW THERAPY DEVICES NEURO NAVIGATION FOR DBS & BCI BIOLOGICS & DRUG DELIVERY 20252023 4 Pillar Growth Strategy by 2025 Target Indications of > 1,000,000 Patients Diagnosed Each Year Potential Total Addressable Market for CLPT of $12B+ Full Market Release for PRISM Neuro Laser Integrate Maestro Tools
Slide 18: Investment highlights
© 2 0 2 3 C L E A R P O I N T N E U R O 18 Unique platform technology enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders Large, growing installed base in 65+ of 500+ leading Neurosurgery and research centers worldwide Expandable Platform wi
Slide 19: Slide 19
Slide 20: ClearPoint Neuro
CLEARPOINT NEURO